
Opinion|Videos|January 23, 2025
Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology
Panelists discuss how they envision the future of industry-provided and other patient support services in hematology-oncology, highlighting potential improvements and innovations that could be implemented in the near future.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What do you think is the future of industry-provided and other patient support services in hematology-oncology, and what improvements or innovations would you like to see implemented in the near future?
Advertisement
Related to this article

Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.

Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.

Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.

In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.

Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Advertisement
Advertisement
Trending on AJMC
1
Using Complement Inhibitors in GA Comes With Pros and Cons
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5

